David Foehr Sells 993 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 993 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $24.02, for a total value of $23,851.86. Following the transaction, the vice president owned 36,758 shares in the company, valued at approximately $882,927.16. This trade represents a 2.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Monday, August 24th, David Foehr sold 859 shares of CeriBell stock. The shares were sold at an average price of $23.95, for a total value of $20,573.05.

CeriBell Stock Performance

CBLL stock traded up $0.01 during mid-day trading on Tuesday, hitting $23.95. 243,381 shares of the company were exchanged, compared to its average volume of 457,237. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The business has a 50 day simple moving average of $19.77 and a 200-day simple moving average of $19.27. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $25.33. The stock has a market capitalization of $919.20 million, a PE ratio of -13.61 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The company had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. On average, equities analysts forecast that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Institutional Investors Weigh In On CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its holdings in shares of CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after acquiring an additional 854 shares in the last quarter. Sei Investments Co. boosted its holdings in CeriBell by 2.3% in the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after acquiring an additional 1,125 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares in the last quarter. Deutsche Bank AG raised its stake in shares of CeriBell by 1.7% in the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock worth $1,868,000 after purchasing an additional 1,393 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of CeriBell in the 1st quarter valued at about $27,000.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. BTIG Research boosted their price objective on shares of CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Barclays upgraded CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Finally, Canaccord Genuity Group increased their price objective on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $22.40.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.